NCT Number,Study Title,Study URL,Acronym,Study Status,Brief Summary,Study Results,Conditions,Interventions,Primary Outcome Measures,Secondary Outcome Measures,Other Outcome Measures,Sponsor,Collaborators,Sex,Age,Phases,Enrollment,Funder Type,Study Type,Study Design,Other IDs,Start Date,Primary Completion Date,Completion Date,First Posted,Results First Posted,Last Update Posted,Locations,Study Documents
NCT00811447,Taxotere New Indication - Gastric Cancer Treatment Registration Trial,https://clinicaltrials.gov/study/NCT00811447,,COMPLETED,"Primary objective:

To detect a statistically significant increase in time to progression (TTP) of disease for the test group (TaxotereÂ® \[Docetaxel\] combined with cisplatin and 5-fluorouracil \[TCF\]) relative to the control group (Cisplatin combined with 5-fluorouracil\[CF\])

Secondary objectives:

* To detect a statistically significant increase in overall survival (OS) for the test group relative to the control group.
* To compare response rate (RR), time to treatment failure (TTF), duration of responses, safety profiles, quality of life (QOL), and disease-related symptoms.",NO,Stomach Neoplasms,DRUG: 5-fluorouracil|DRUG: Cisplatin|DRUG: Docetaxel,"Time to progression, Throughout the study period","Safety profile, Throughout the study period|Overall survival, From beginning to end of study|Tumor response, every 8 weeks|Clinical toxicities/symptomatology, Throughout the study period|Laboratory toxicities/symptomatology, Throughout the study period",,Sanofi,,ALL,"ADULT, OLDER_ADULT",PHASE3,243,INDUSTRY,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,DOCET_L_02195,2008-11,2012-06,2012-06,2008-12-19,,2012-08-31,"Sanofi-Aventis Administrative Office, Shanghai, China",
